Attovia Therapeutics (NASDAQ:ATTO) Major Shareholder Life Sciences Xi L.P. Frazier Buys 588,235 Shares

Attovia Therapeutics, Inc. (NASDAQ:ATTO) major shareholder Life Sciences Xi L.P. Frazier acquired 588,235 shares of the stock in a transaction dated Thursday, August 6th. The shares were purchased at an average price of $17.00 per share, for a total transaction of $9,999,995.00. Following the completion of the purchase, the insider directly owned 6,154,213 shares in the company, valued at $104,621,621. The trade was a 10.57% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Attovia Therapeutics Price Performance

Attovia Therapeutics stock opened at $20.38 on Friday. Attovia Therapeutics, Inc. has a 52 week low of $19.63 and a 52 week high of $22.79.

About Attovia Therapeutics

Attovia Therapeutics, Inc (NASDAQ: ATTO) is a clinical-stage biopharmaceutical company developing antibody-based medicines for inflammatory and immune-mediated diseases. The company’s research is focused on creating differentiated biologic therapies intended to address significant unmet medical needs.

Attovia uses proprietary antibody-engineering technologies to discover and develop therapeutic candidates, including multispecific antibodies designed to modulate disease-related biological pathways.